We use cookies to collect information about how you use GOVUnited Kingdom We use this information to make the website the best we can and to improve government services

Janssen today released positive data from the Phase 3 trials of its single-dose COVID-19 vaccine candidate showing it was 66% overall effective in preventing coronavirus in participants

Janssen has today (29 January) published positive data from Phase 3 studies of its single-dose COVID-19 vaccine candidate showing it was 66% overall effective in preventing the coronavirus in participants, and the data did not reveal any significant safety concerns in Regarding the vaccine reported without serious adverse events occurring in vaccine recipients

The UK received 30 million doses of the vaccine from Janssen last summer Deliveries are expected to arrive in the second half of this year when they are approved for use by the Medicines and Health Products Regulatory Agency (MHRA), which will review the vaccine and analyze relevant data to determine if the vaccine meets strict safety and security standards Effectiveness standards corresponds to

Today’s results relate to Janssen’s single-dose study. Phase 3 studies for the company’s 2-dose regimen are ongoing worldwide, including in the UK at 16 National Institute for Health Research (NIHR) sites across the country are more than 6000 volunteers in the UK involved, some of whom were recruited from the NHS vaccine registry

While a single dose of a safe and effective vaccine would provide a significant benefit during a global pandemic emergency, a 2-dose plan may potentially offer longer lifespans for some participants. Data from this multi-country study is expected later this year

This is even more encouraging news from Janssen following the positive trial results from Novavax last night and the news that Valneva started vaccine production in Scotland this week

Thanks to the life-saving work of our Vaccine Taskforce, the UK quickly received 30 million doses of Janssen’s vaccine last summer. If this vaccine is approved by our Medicines Agency, we are expected to receive the doses in the second half of this year

To date, the UK government has had early access to a bumper portfolio of 367 million vaccine doses from seven different vaccine developers, with Janssen’s vaccine being the fifth to release its Phase 3 results

The Janssen vaccine works in the same way as the vaccine developed by Oxford and AstraZeneca and is designed to elicit an immune response, including neutralizing antibodies to the spike protein to eliminate the virus, similar to the Oxford / AstraZeneca vaccine, it can safely be be stored and transported at normal refrigeration temperatures

This is more good news from Janssen on vaccines If this push is approved, it could significantly improve our vaccination program, especially as a single dose vaccine

Once the complete data has been submitted to the regulatory agency, they will use the evidence to verify that the vaccine meets strict standards for safety, efficacy and quality

With more than 7 vaccines we will continue to roll out across the UK as soon as possible, 4 million people have received their first dose so far

It’s encouraging to see more positive news about vaccines getting through so quickly – this time from Janssen. Just a few months ago there were doubts as to whether a COVID-19 vaccine would even be possible – now 5 companies have good Phase 3 results released, 3 vaccines have been approved and over 7 million people have received their first bursts

Vaccination is the way out of this pandemic, and I am once again grateful to all the volunteers who made these studies possible

The Vaccines Task Force gave the UK early access to 367 million doses of 7 of the most promising vaccines to date. To date, the UK government has invested over £ 230 million in making a successful vaccine

The UK was the first country in the world to source, approve and then use the Oxford / AstraZeneca and Pfizer / BioNTech vaccines

Production of the University of Oxford / AstraZeneca vaccine began last fall, when the bulk of the vaccine for the UK is manufactured in Oxfordshire and Staffordshire and bottled in North Wales

A total of more than 74 million people across the UK have now received at least one dose of the vaccine

The vaccine supply and planned government shipments will fully support our goal of offering a first dose of vaccine to every person in the top 4 priority groups by mid-February

The members of the Joint Vaccination and Immunization Committee (JCVI) are independent experts who advise the UK on prioritizing all vaccination and vaccination programs at the population level You have created the prioritization list of the patient groups running the NHS vaccination program, and the committee is reviewing its recommendations and updating them as necessary

The government has established a process for the approval of vaccines which is monitored by the MHRA.This includes the approval of a product license by MHRA after the applicant has compiled suitable data to demonstrate the quality, safety and effectiveness of the vaccine

In total, the government has procured 60 million doses of the Novavax candidate, the majority of which will be made in the UK if the vaccine is approved by regulators

The UK’s Vaccine Taskforce has given early access to 367 million doses of 7 of the most promising vaccine candidates, including:

The UK Government, in partnership with Cell and Gene Therapy Catapult, has invested £ 127 million to fund a state-of-the-art manufacturing innovation center in Braintree, Essex, to accelerate the mass production of a successful COVID-19 vaccine in the UK Due When it opens in December 2021, the center will be able to produce millions of doses of vaccine every month to ensure the UK’s future ability to manufacture both vaccines and advanced medicines, including for emerging diseases / p>

The government has also allocated £ 4.7 million funding for the catapult to ensure the UK has the best skills and expertise in vaccine and advanced therapy manufacturing

The government has set up a Rapid Deployment Facility with a £ 875 million investment in large-scale vaccine manufacturing

The government has also set up the UK’s first dedicated Vaccine Manufacturing and Innovation Center (VMIC) and has invested 93 million in its development GBP Accelerated This investment will speed up the construction of the facility quickly and allow us to get it online sooner It will also provide expanded opportunities for advanced vaccination process development, filling and finishing, and mass production, and will greatly increase the facility’s capacity, to respond to this pandemic.Once opened, it will be able to produce 70 million doses of vaccine in just 6 months – enough for the UK population.The Oxfordshire center will be the UK’s first non-profit organization created to develop the mass production of vaccines and move forward This will increase the UK’s long-term capacity against future viruses

To help us improve the GOV UK, today we’d like to know more about your visit We’ll send you a link to a feedback form It only takes 2 minutes to fill out Don’t worry, we won’t spam you or give you your email Mail address to no one else

Open Government License

Efficacy

World News – GB – Janssen Releases Positive Safety and Efficacy Data for Single-Dose COVID-19 Vaccine

Source: https://www.gov.uk/government/news/janssen-publishes-positive-safety-and-efficacy-data-for-single-dose-covid-19-vaccine